MediXall Group Reports Zero Revenue, Continued Losses in Q2 2024

Medixall Group, Inc. 10-Q Filing Summary
Field	Detail
Company	Medixall Group, Inc.
Form Type	10-Q
Filed Date	Jun 5, 2025
Risk Level	high
Sentiment	bearish

Sentiment: bearish

Topics: Healthcare Technology, Zero Revenue, Net Loss, Accumulated Deficit, Micro-cap, High Risk, Startup Phase

TL;DR

MediXall Group is a cash-burning health tech hopeful with no revenue, making it a speculative bet at best.

AI Summary

MediXall Group, Inc. reported no revenue for the three and six months ended June 30, 2024, and June 30, 2023, indicating a lack of operational income. The company incurred net losses of $1,000 for the three months ended June 30, 2024, and $2,000 for the six months ended June 30, 2024. These figures represent a decrease from the net losses of $2,000 and $4,000 for the comparable periods in 2023, respectively. The primary business change noted is the continued focus on its healthcare technology platform, Health Karma, despite the absence of revenue generation. Key risks include the company's accumulated deficit of $28,000,000 as of June 30, 2024, and its reliance on external financing to fund operations. The strategic outlook remains centered on developing and commercializing its Health Karma platform, but without clear milestones or funding details, its viability is questionable. The company's balance sheet shows total assets of $1,000 as of June 30, 2024, unchanged from December 31, 2023, and total liabilities of $1,000 as of June 30, 2024, also unchanged from December 31, 2023.

Why It Matters

For investors, MediXall Group's persistent lack of revenue and substantial accumulated deficit of $28,000,000 as of June 30, 2024, signals significant operational challenges and a high-risk investment. Employees face uncertainty given the company's reliance on external financing and unproven business model in a competitive healthcare technology market. Customers of the Health Karma platform, if any, might question the long-term viability and support for the service. The broader market sees another micro-cap struggling to gain traction, highlighting the difficulties in scaling health tech innovations without substantial capital or clear market penetration.

Risk Assessment

Risk Level: high — The risk level is high due to zero revenue reported for both the three and six months ended June 30, 2024, and an accumulated deficit of $28,000,000 as of June 30, 2024. This indicates a severe lack of operational income and significant financial instability, relying entirely on external funding.

Analyst Insight

Investors should exercise extreme caution and avoid MediXall Group, Inc. given its zero revenue, substantial accumulated deficit, and unproven business model. This company is highly speculative and presents significant downside risk.

Financial Highlights

debt To Equity: N/A
revenue: $0
operating Margin: N/A
total Assets: $1,000
total Debt: N/A
net Income: -$1,000
eps: N/A
gross Margin: N/A
cash Position: N/A
revenue Growth: N/A

Revenue Breakdown

Segment	Revenue	Growth
Health Karma Platform	$0	N/A

Key Numbers

$0 — Revenue (for three and six months ended June 30, 2024, indicating no operational income)
$1,000 — Net Loss (for the three months ended June 30, 2024, a decrease from $2,000 in 2023)
$2,000 — Net Loss (for the six months ended June 30, 2024, a decrease from $4,000 in 2023)
$28,000,000 — Accumulated Deficit (as of June 30, 2024, highlighting significant past losses)
$1,000 — Total Assets (as of June 30, 2024, unchanged from December 31, 2023)
$1,000 — Total Liabilities (as of June 30, 2024, unchanged from December 31, 2023)

Key Players & Entities

MediXall Group, Inc. (company) — filer of the 10-Q
Health Karma (company) — healthcare technology platform
SEC (regulator) — recipient of the 10-Q filing
$28,000,000 (dollar_amount) — accumulated deficit as of June 30, 2024
$1,000 (dollar_amount) — net loss for three months ended June 30, 2024
$2,000 (dollar_amount) — net loss for six months ended June 30, 2024
$1,000 (dollar_amount) — total assets as of June 30, 2024
$1,000 (dollar_amount) — total liabilities as of June 30, 2024

FAQ

What was MediXall Group's revenue for Q2 2024?

MediXall Group, Inc. reported zero revenue for the three months ended June 30, 2024, and also for the six months ended June 30, 2024.

What was MediXall Group's net income for the second quarter of 2024?

MediXall Group, Inc. reported a net loss of $1,000 for the three months ended June 30, 2024, and a net loss of $2,000 for the six months ended June 30, 2024.

What is the accumulated deficit for MediXall Group as of June 30, 2024?

As of June 30, 2024, MediXall Group, Inc. had an accumulated deficit of $28,000,000.

What is the primary business focus of MediXall Group?

MediXall Group's primary business focus is the development and commercialization of its healthcare technology platform, Health Karma.

What are the main risks for investors in MediXall Group?

Key risks for investors include the company's zero revenue, substantial accumulated deficit of $28,000,000, and its reliance on external financing to fund operations without a proven revenue model.

How do MediXall Group's Q2 2024 results compare to Q2 2023?

MediXall Group reported zero revenue in both periods. Net loss for Q2 2024 was $1,000, an improvement from a $2,000 net loss in Q2 2023. For the six months, net loss was $2,000 in 2024, compared to $4,000 in 2023.

What are MediXall Group's total assets and liabilities as of June 30, 2024?

As of June 30, 2024, MediXall Group, Inc. reported total assets of $1,000 and total liabilities of $1,000.

Is MediXall Group generating any cash from operations?

Based on the zero revenue reported for the three and six months ended June 30, 2024, MediXall Group is not generating any cash from its operations.

What is the significance of MediXall Group's accumulated deficit?

The accumulated deficit of $28,000,000 signifies that the company has incurred significant losses since its inception, indicating a history of unprofitability and a need for substantial future earnings to offset these losses.

What is the outlook for MediXall Group's Health Karma platform?

The outlook for the Health Karma platform is uncertain, as the company continues to develop it but has not yet generated any revenue from it, indicating a lack of market penetration or monetization.

Risk Factors

Significant Accumulated Deficit [high — financial]: The company has an accumulated deficit of $28,000,000 as of June 30, 2024. This indicates substantial historical losses that have eroded equity.
Reliance on External Financing [high — financial]: MediXall Group relies on external financing to fund its operations. The absence of revenue generation exacerbates this reliance, posing a risk to continued operations.
Lack of Revenue Generation [high — operational]: The company reported $0 revenue for the three and six months ended June 30, 2024. This lack of operational income raises concerns about the viability of its business model and strategy.
Uncertainty of Health Karma Platform Commercialization [medium — operational]: The company's strategic focus is on its Health Karma platform, but there are no clear milestones or funding details provided for its commercialization, making its success uncertain.

Industry Context

The healthcare technology sector is highly competitive, with companies focusing on digital platforms for patient engagement, data management, and remote care. Success often hinges on robust product development, effective commercialization strategies, and securing significant funding to scale operations. MediXall Group operates within this dynamic environment, aiming to leverage its Health Karma platform.

Regulatory Implications

As a healthcare technology company, MediXall Group may be subject to various regulations concerning data privacy (e.g., HIPAA in the U.S.) and the efficacy of its platform. Compliance with these regulations is crucial for market access and avoiding penalties, though specific regulatory risks are not detailed in the provided summary.

What Investors Should Do

Monitor for revenue generation milestones.
Seek clarity on funding strategy.
Evaluate the commercialization plan for Health Karma.

Key Dates

2024-06-30: Quarterly Report Filing (10-Q) — Provides the latest financial performance and operational updates for the period ending June 30, 2024.
2023-06-30: Prior Period Comparison — Used for year-over-year comparison of financial metrics, showing a reduction in net losses.

Glossary

Accumulated Deficit: The cumulative net losses of a company since its inception, which reduces shareholders' equity. (Highlights MediXall Group's significant historical unprofitability, with a deficit of $28,000,000 as of June 30, 2024.)
10-Q: A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information for MediXall Group for the period ending June 30, 2024.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, MediXall Group has reduced its net losses, reporting $1,000 for the three months ended June 30, 2024 (down from $2,000 in 2023) and $2,000 for the six months ended June 30, 2024 (down from $4,000 in 2023). However, revenue remains at $0 in both periods, and the company's balance sheet shows minimal assets and liabilities of $1,000 each, unchanged from the prior year-end. The significant accumulated deficit of $28,000,000 persists as a major concern.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on June 5, 2025 regarding MediXall Group, Inc..

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR